327 related articles for article (PubMed ID: 16278881)
1. Osteogenesis imperfecta, current and future medical treatment.
Rauch F; Glorieux FH
Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
Rauch F; Glorieux FH
Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
[TBL] [Abstract][Full Text] [Related]
3. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
4. Experience with bisphosphonates in osteogenesis imperfecta.
Glorieux FH
Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of osteogenesis imperfecta with bisphosphonates].
Tau C
Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
[TBL] [Abstract][Full Text] [Related]
6. Treatment of children with osteogenesis imperfecta.
Rauch F; Glorieux FH
Curr Osteoporos Rep; 2006 Dec; 4(4):159-64. PubMed ID: 17112427
[TBL] [Abstract][Full Text] [Related]
7. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
9. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
Malmgren B; Aström E; Söderhäll S
J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
[TBL] [Abstract][Full Text] [Related]
11. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
12. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment].
Brixen KT; Illum NO; Hansen B; Lund AM; Mosekilde L
Ugeskr Laeger; 2007 Jan; 169(1):30-4. PubMed ID: 17217883
[TBL] [Abstract][Full Text] [Related]
13. Osteogenesis imperfecta: questions and answers.
Shapiro JR; Sponsellor PD
Curr Opin Pediatr; 2009 Dec; 21(6):709-16. PubMed ID: 19907330
[TBL] [Abstract][Full Text] [Related]
14. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
15. Osteogenesis imperfecta.
Bhadada SK; Santosh R; Bhansali A; Upreti V; Dutta P
J Assoc Physicians India; 2009 Jan; 57():33-6. PubMed ID: 19753756
[TBL] [Abstract][Full Text] [Related]
16. The use of bisphosphonates in children with osteogenesis imperfecta.
Glorieux FH
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1491-5. PubMed ID: 11837505
[TBL] [Abstract][Full Text] [Related]
17. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
18. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
Aström E; Magnusson P; Eksborg S; Söderhäll S
Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
20. Characterising and treating osteogenesis imperfecta.
Bishop N
Early Hum Dev; 2010 Nov; 86(11):743-6. PubMed ID: 20846798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
